For years, intravenous vitamin C has been administered to severe burn patients based on the premise that its antioxidant and vascular-stabilizing properties could reduce fluid resuscitation needs and improve survival. The VICTORY trial now delivers a definitive rebuttal to that clinical assumption, with implications extending beyond burn units to any critical-care setting where high-dose vitamin C is being used off-label.
The international randomized clinical trial, published in JAMA, evaluated high-dose intravenous vitamin C in patients with large burns. The study incorporated pre-specified stopping rules based on futility or harm — a rigorous design feature that reflects genuine equipoise at the outset. The results showed no improvement in clinical outcomes, and the data trended toward increased mortality in the vitamin C group, prompting serious concern rather than mere disappointment about the intervention's safety profile.
This finding matters beyond burn care. High-dose intravenous vitamin C gained widespread attention following observational data and smaller trials suggesting benefit in sepsis, COVID-19-associated critical illness, and cancer. The VICTORY trial joins a growing body of evidence — including the CITRIS-ALI trial in sepsis and the LOVIT trial in ICU patients — that has repeatedly failed to confirm benefit from this approach in critically ill populations. The pattern is becoming difficult to dismiss as coincidence. A plausible biological mechanism exists, but mechanism does not equal efficacy. What distinguishes VICTORY is its scale, international design, and the concerning mortality signal, which elevates this from a null result to a potential safety warning. For health-conscious adults supplementing with oral vitamin C, the pharmacokinetics differ vastly from intravenous megadosing, so direct extrapolation is unwarranted. However, this trial should substantially dampen enthusiasm for high-dose IV protocols in clinical settings until further evidence clarifies who, if anyone, might benefit.